抗肿瘤血管生成及其联合放化疗的研究进展

Advances in anti-tumor angiogenesis and combinated with radiotherapy or chemotherapy

抗血管生成治疗肿瘤的理论基础是肿瘤的生长对血管生成的依赖性。新生血管为肿瘤的生长、转移提供氧和营养物质,在无新生血管生成时,实体肿瘤的生长明显被抑制,只局限于原位癌或几百个微米的微转移;而一旦新生血管长入,肿瘤将迅速生长,且浸润和转移的能力大大加强。Folkman把这一现象称为“血管生长切换机制”。目前,以抗血管生成为目的的肿瘤治疗策略日益成为国内外关注和研究的焦点,而且在动物试验中已显示出独特的抗肿瘤效应,不过由于肿瘤血管生成的复杂性、异时性及抗肿瘤血管生成疗法自身作用的局限性等原因,其临床疗效并不很理想。于是,人们把目光投向了与传统的放射治疗、化学治疗的联合治疗上。近年来的研究表明,联合治疗具有协同抗肿瘤作用。

It is the theoretical basis of anti-tumor angiogenesis therapy that tumor growth and metastasis is angiogenesis-dependent. Neonatal blood vessel provides tumor growth and metastasis with oxygen and nutrition. When no angiogenesis, solid tumor growth will Be inhibited so obviously that it is limited to carcinoma or tiny metastasis of several hundred micra; on the contrary, if having angiogenesis, tumor will grow rapidly, whacs more, its nature of soakage and metastasis will be enhanced greatly. Folkman termed this phenomenon as the balance forth angiogenesis switch. At present, anti-tumor angiogenesis strategies are increasingly becoming a focus of attention and study worldwide, and it has showed uniqe anti-tumor effect in animal trials. But for the complexity and the asynchronism of tumor angiogenitic and the limitation of anti-tumor angiogenesis therapy itself, its clinical effect is not too satisfying. Therefore scientists pay more attention to combination therapy with traditional radiotherapy and chemotherapy. Present studies have already proved synergistic anti-tumor effects of combination therapy.